MDRX · As filed with the SEC
Veradigm income statement, by fiscal year
The statement as Veradigm presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED STATEMENTS OF OPERATIONS · USD
| USD | FY2024 Year ended Dec 31, 2024 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 | FY2020 Year ended Dec 31, 2020 |
|---|---|---|---|---|
| Revenue | 594,410,000 | 588,017,000 | 577,427,000 | 556,115,000 |
| Payer & Life Science | — | 122,090,000 | 99,009,000 | 93,080,000 |
| Provider | 473,065,000 | 465,927,000 | 478,418,000 | 463,035,000 |
| Provider | — | 232,758,000 | 244,171,000 | 247,763,000 |
| Payer & Life Science | — | 46,839,000 | 50,810,000 | 44,118,000 |
| Cost of revenue | 292,165,000 | 279,597,000 | 294,981,000 | 291,881,000 |
| Gross profit | 302,245,000 | 308,420,000 | 282,446,000 | 264,234,000 |
| Selling, general and administrative expenses | 269,406,000 | 169,201,000 | 111,760,000 | 155,663,000 |
| Research and development | 108,255,000 | 97,889,000 | 84,103,000 | 78,605,000 |
| Asset impairment charges | — | 7,549,000 | 532,000 | 10,174,000 |
| Amortization of intangible and acquisition-related assets | — | 60,884,000 | 9,282,000 | 11,852,000 |
| Impairment of goodwill and other assets | 108,218,000 | — | — | — |
| Amortization of intangibles | 11,027,000 | — | — | — |
| Income (loss) from operations | (194,661,000) | (27,103,000) | 76,769,000 | 7,940,000 |
| Loss on debt extinguishment | (17,632,000) | — | — | — |
| Interest expense | (15,045,000) | (6,354,000) | (12,925,000) | (34,345,000) |
| Interest income | 16,231,000 | — | — | — |
| Insurance recoveries | 5,000,000 | — | — | — |
| Other income (expense), net | (8,230,000) | (21,676,000) | 88,889,000 | (1,929,000) |
| Gain (loss) on sale of businesses, net | — | 0 | 8,370,000 | 0 |
| Impairment of long-term investments | — | (7,575,000) | (5,155,000) | (1,575,000) |
| Equity in net income (loss) of unconsolidated investments | — | (1,143,000) | 1,757,000 | 17,348,000 |
| Impairment of long-term investments | (575,000) | — | — | — |
| Income (loss) from continuing operations before income taxes | 214,912,000 | (63,851,000) | 157,705,000 | (12,561,000) |
| Income tax benefit (provision) | (69,492,000) | 43,807,000 | (29,927,000) | (15,128,000) |
| Income (loss) from consolidated continuing operations, net of tax | (284,404,000) | (20,044,000) | 127,778,000 | (27,689,000) |
| Equity in net loss of unconsolidated subsidiaries, net of tax | (7,175,000) | — | — | — |
| Income (loss) from continuing operations, net of tax | (291,579,000) | — | — | — |
| Loss from discontinued operations | 0 | (7,122,000) | 15,727,000 | (70,884,000) |
| Loss on sale of discontinued operations | 0 | (10,327,000) | 647,000 | 1,156,815,000 |
| Income tax effect on discontinued operations | 0 | (48,969,000) | (4,587,000) | (362,190,000) |
| Loss from discontinued operations, net of tax | 0 | (66,418,000) | 11,787,000 | 723,741,000 |
| Net income (loss) | (291,579,000) | (86,462,000) | 139,565,000 | 696,052,000 |
| Net loss attributable to noncontrolling interests | 37,000 | — | — | — |
| Net income (loss) attributable to Veradigm Inc. | (291,542,000) | — | — | — |
| Basic | ||||
| Continuing operations | (2.7) | (0.18) | 0.98 | (0.17) |
| Discontinued operations | 0 | (0.59) | 0.09 | 4.54 |
| Net basic earnings (loss) per common share | (2.7) | (0.77) | 1.07 | 4.37 |
| Diluted | ||||
| Continuing operations | (2.7) | (0.18) | 0.92 | (0.17) |
| Discontinued operations | 0 | (0.59) | 0.09 | 4.54 |
| Net income (loss) per share - Diluted | (2.7) | (0.77) | 1.01 | 4.37 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.